Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board approved audited financial results for FY ended March 31, 2026 and recommended a final dividend of Rs. 0.50 per share (10% on Rs. 5 face value), with record date July 3, 2026 and payment by August 31, 2026. The Board also approved acquiring the remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) through a share swap — issuing 87,92,317 Biocon shares at Rs. 376.16 per share, valued at Rs. 330.73 Crores. Post-acquisition, Biocon's holding in BBL will rise from ~99% to ~99.99%. Additionally, statutory auditors will change from B S R & Co. LLP to S. R. Batliboi & Associates LLP for 5 years, and the Board approved appointments of 6 new directors including industry veterans like Rajiv Malik (former Viatris/Mylan President) and Peter Piot (Ebola co-discoverer). A new Long-Term Incentive Plan (Biocon Unity LTIP 2026) was also approved. The 48th AGM is scheduled for August 6, 2026.
The BBL integration into a wholly-owned subsidiary simplifies Biocon's corporate structure and could unlock operational synergies. The share swap will dilute existing shareholders by ~87.92 lakh shares but strengthens control over BBL's biosimilar portfolio. Dividend recommendation provides income to shareholders. The new board composition with global pharma veterans signals strategic intent ahead.